Gür, DenizHasçelik, Ayşe GülşenAydın, NerimanTelli, MuratGültekin, MeralOgünç, DilaraArıkan, Osman AtillaUysal, SevilYaman, AkgünKibar, FilizGülay, ZeynepSümerkan, BülentEsel, DuyguKayacan, CiğdemAktaş, ZerrinSöyletir, GünerAltınkanat, GülşenDurupınar, BelmaDarka, ÖzgeAkgün, YurdanurYayla, BuketBerktaş, MustafaYaman, Görkem2022-04-262022-04-262009-08Gür, D. vd. (2009). "Antimicrobial resistance in Gram-negative hospital isolates: Results of the Turkish HITIT-2 surveillance study of 2007". Journal of Chemotherapy, 21(4), 383-389.1120-009Xhttps://doi.org/10.1179/joc.2009.21.4.383https://www.tandfonline.com/doi/abs/10.1179/joc.2009.21.4.383http://hdl.handle.net/11452/26068Resistance rates to amikacin, ciprofloxacin, ceftazidime, cefepime, imipenem, cefoperazone/sulbactam and piperacillin/tazobactam in Escherichia coli (n = 438), Klebsiella pneumoniae (n = 444), Pseudomonas aeruginosa (n = 210) and Acinetobacter baumanni (n =200) were determined with E-test in a multicenter surveillance study (HITIT-2) in 2007. ESBL production in Escherichia coli and K. pneumoniae was investigated following the CLSI guidelines. Overall 42.0% of E.coli and 41.4% of K. pneumoniae were ESBL producers. In E. coli, resistance to imipenem was not observed, resistance to ciprofloxacin and amikacin was 58.0% and 5.5% respectively. In K. pneumoniae resistance to imipenem, ciprofloxacin and amikacin was 3.1%, 17.8% 12.4% respectively. In P. aeruginosa the lowest rate of resistance was observed with piperacillin/tazobactam (18.1%). A. baumanni isolates were highly resistant to all the antimicrobial agents, the lowest level of resistance was observed against cefoperazone/sulbactam (52.0%) followed by imipenem (55.5%). This study showed that resistance rates to antimicrobials are high in nosocomial isolates and show variations among the centers.eninfo:eu-repo/semantics/closedAccessA. BaumanniiAntimicrobial resistanceE.coliESBLGram-negative bacteriaK. PneumoniaeP. Aeruginosaβ-lactamase inhibitorSpectrum beta-lactamasesKlebsiella-pneumoniaeEscherichia-coliTurkeySusceptibilityCarbapenemasesOxacillinasePrevalenceMechanismsOrganismsOncologyInfectious diseasesPathologyPharmacology & pharmacyArticle0002694141000032-s2.0-7034921018738338921419622455OncologyInfectious diseasesPathologyPharmacology & pharmacyTigecycline; Carbapenem Derivative; Antibiotic ResistanceAmikacinAntibiotic agentCeftazidimeCiprofloxacinExtended spectrum beta lactamaseImipenemPiperacillin plus tazobactamSulperazonAcinetobacter baumanniiAntibiotic resistanceAntibiotic sensitivityArticleBacterium identificationBacterium isolateBloodCerebrospinal fluidEscherichia coliGram negative bacteriumHospital infectionHospital patientKlebsiella pneumoniaeLung lavageMicrobiologyMinimum inhibitory concentrationNonhumanPseudomonas aeruginosaUrine